Company Info
Fennec Pharmaceuticals Inc. is a Canadian biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer. Founded in 1996 and headquartered in Toronto, Ontario, Fennec is dedicated to addressing unmet medical needs in pediatric oncology. The company's lead product candidate, PEDMARK™ (sodium thiosulfate), is in late-stage clinical development for the prevention of ototoxicity induced by cisplatin chemotherapy in children. Ototoxicity, or hearing loss, is a common and severe side effect of cisplatin treatment, particularly in pediatric patients. By developing PEDMARK™, Fennec aims to provide a potential solution to this significant medical challenge and improve the quality of life for pediatric cancer patients. In addition to PEDMARK™, Fennec is committed to advancing its pipeline of novel therapies aimed at improving outcomes for cancer patients. Through strategic partnerships, clinical research collaborations, and regulatory initiatives, Fennec Pharmaceuticals continues its mission to bring innovative treatments to market and make a meaningful impact in the field of oncology.